PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'ReVacc Scientific, Frederick, MD, USA.\', \'Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.\', \'ReVacc Biotech, Frederick, MD, USA.\', \'Bioqual, Rockville, MD, USA.\', \'Experimental Pathology Laboratories, Sterling, VA, USA.\', \'Institute for Bioscience and Biotechnology Research, Rockville, MD, USA.\', \'Department of Microbiology and Immunology and Center of Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1080/22221751.2021.1994354
?:hasPublicationType
?:journal
  • Emerging microbes & infections
is ?:pmid of
?:pmid
?:pmid
  • 34651563
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34651563>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34651563>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all